Press Release Stockholm, Sweden, December 22, 2023 Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, announced an update on the status and outlook of.
Press Release Stockholm, Sweden, December 13, 2023 At the extraordinary general meeting of Mendus AB , reg. no. 556629-1786, , on 13 December 2023 the EGM adopted, inter alia,.
Press Release Stockholm, Sweden, December 11, 2023 As of November 24, 2023, median relapse-free survival stood at 30.4 months Median overall survival was not reached, with the majority of.
Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Mendus And Australasian Leukaemia & Lymphoma Group To Expand Clinical Testing Of Vididencel As Maintenance Treatment For AML menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.